百济神州
ONC269.630USD
-6.899-2.50%
收盘 06/13, 16:00（美东）报价延迟15分钟
26.72B总市值
亏损市盈率 TTM
关于 Beigene Ltd 公司
百济神州有限公司是一家全球生物科技公司，致力于为全球癌症患者发现和开发肿瘤治疗药物。该公司已发现和开发了三种获批药物，包括 BRUKINSA，一种用于治疗各种血癌的布鲁顿酪氨酸激酶小分子抑制剂；TEVIMBRA（替雷利珠单抗），一种用于治疗各种实体瘤和血癌的抗 PD-1 抗体免疫疗法；以及帕米帕尼，一种选择性聚 ADP-核糖聚合酶 1 (PARP1) 和 PARP2 小分子抑制剂。该公司已获准在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售 BRUKINSA；在欧盟和中国销售替雷利珠单抗；在中国销售帕米帕尼。该公司还专注于在安进公司 (Amgen Inc.) 的独家许可下在中国商业化 XGEVA、BLINCYTO、KYPROLIS 等抗癌药物。
公司简介
公司代码ONC
公司名称Beigene Ltd
上市日期- -
成立日期2010
CEOMr. John Victor Oyler
员工数量11000
证券类型Ordinary Share
年结日- -
公司地址c/o Mourant Governance Services (Cayman)
城市GRAND CAYMAN
上市交易所The Toronto Stock Exchange
国家Cayman Islands
邮编KY1-1108
电话13459494123
网址https://www.beigene.com/
公司代码ONC
上市日期- -
成立日期2010
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
地区USD
名称
营收
占比
United States
1.96B
51.37%
China
1.41B
37.04%
Europe
362.63M
9.52%
ROW
78.81M
2.07%
业务
地区
业务USD
名称
营收
占比
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
股东统计
更新时间: 6月3日 周二
更新时间: 6月3日 周二
持股股东
股东类型
持股股东
持股股东
占比
Amgen Inc
17.29%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.65%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.10%
持股股东
持股股东
占比
Amgen Inc
17.29%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.65%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.10%
股东类型
持股股东
占比
Investment Advisor
21.70%
Corporation
17.31%
Hedge Fund
10.90%
Investment Advisor/Hedge Fund
4.86%
Sovereign Wealth Fund
1.32%
Research Firm
0.89%
Pension Fund
0.21%
Bank and Trust
0.11%
Family Office
0.02%
Other
42.68%
机构持股
更新时间: 1月20日 周一
更新时间: 1月20日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
559
66.79M
67.51%
+1.06M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
2022Q4
657
69.40M
73.25%
-5.85M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Amgen Inc
18.94M
19.16%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.9%
-732.83K
-7.69%
Feb 28, 2025
Capital International Investors
6.11M
6.18%
-317.72K
-4.94%
Dec 31, 2024
PRIMECAP Management Company
5.10M
5.16%
+124.61K
+2.51%
Dec 31, 2024
Baillie Gifford & Co.
3.67M
3.71%
-34.56K
-0.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.78M
1.8%
+174.46K
+10.84%
Dec 31, 2024
T. Rowe Price Associates, Inc.
1.49M
1.51%
+109.68K
+7.93%
Dec 31, 2024
T. Rowe Price International Ltd
1.44M
1.46%
+127.40K
+9.67%
Dec 31, 2024
HHLR Advisors, Ltd.
1.32M
1.34%
-2.48M
-65.19%
Mar 03, 2025
Temasek Holdings Pte. Ltd.
1.53M
1.54%
-863.25K
-36.14%
Dec 31, 2024
查看更多
持股ETF
更新时间: 6月2日 周一
更新时间: 6月2日 周一
机构名称
占比
First Trust NYSE Arca Biotechnology Index Fund
3.51%
Innovator IBD 50 Fund ETF
3.07%
Tema Oncology ETF
2.94%
Virtus LifeSci Biotech Products ETF
2.51%
VanEck Biotech ETF
2.23%
Global X Aging Population ETF
2.05%
iShares Health Innovation Active ETF
1.51%
iShares Biotechnology ETF
1.42%
Invesco Nasdaq Biotechnology ETF
1.17%
ProShares Ultra Nasdaq Biotechnology
1.17%
查看更多
First Trust NYSE Arca Biotechnology Index Fund
占比3.51%
Innovator IBD 50 Fund ETF
占比3.07%
Tema Oncology ETF
占比2.94%
Virtus LifeSci Biotech Products ETF
占比2.51%
VanEck Biotech ETF
占比2.23%
Global X Aging Population ETF
占比2.05%
iShares Health Innovation Active ETF
占比1.51%
iShares Biotechnology ETF
占比1.42%
Invesco Nasdaq Biotechnology ETF
占比1.17%
ProShares Ultra Nasdaq Biotechnology
占比1.17%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
